| Trial ID: | L4562 |
| Source ID: | NCT00138619
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: vildagliptin
|
| Outcome Measures: |
Primary: Safety during 104 weeks of treatment|Change from baseline in HbA1c at 104 weeks | Secondary: Change in HbA1c between 24 weeks and 104 weeks|Change from baseline in fasting plasma glucose at 104 weeks|Change in fasting plasma glucose between 24 weeks and 104 weeks|Change from baseline in HOMA B at 104 weeks|Change in HOMA B between 24 weeks and 104 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
478
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-11
|
| Completion Date: |
2007-04
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-07
|
| Locations: |
Novartis Pharmaceuticals, East Hanover, New Jersey, 07936, United States|Investigative Centers, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00138619
|
